Intellia's Hereditary Angioedema Candidate Shows Reduction In Associated Biomarkers, Attack Rates

Intellia's Hereditary Angioedema Candidate Shows Reduction In Associated Biomarkers, Attack Rates
  • Intellia Therapeutics Inc NTLA announced updated data from an ongoing Phase 1/2 study of NTLA-2002 for hereditary angioedema (HAE). 
  • Single doses of 25 mg (n=3), 50 mg (n=4), and 75 mg (n=3) of NTLA-2002 were administered via intravenous infusion.
  • Administration of NTLA-2002 led to deep, dose-dependent reductions in plasma kallikrein. 
  • For the 25 mg and 75 mg cohorts, these deep reductions in plasma kallikrein were sustained through the observation period, which ranged from week 16 to week 32.
  • Related: Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies.
  • All patients treated in the 25 mg and 75 mg cohorts have an ongoing attack-free interval through the latest follow-up.
  • The first three patients treated have an ongoing attack-free interval of 5.5 – 10.6 months after a single dose of NTLA-2002.
  • At all three dose levels, NTLA-2002 was generally well-tolerated, and the majority of adverse events were mild in severity. 
  • Intellia expects to select up to two doses to further evaluate NTLA-2002 in the Phase 2 study, which is expected to begin in 1H of 2023. 
  • Price Action: NTLA shares closed higher by 4.17% at $54.95 on Friday.

Posted In: BriefsBiotechNewsHealth CareGeneral